53.27
Inspire Medical Systems Inc stock is traded at $53.27, with a volume of 783.12K.
It is up +5.28% in the last 24 hours and up +25.02% over the past month.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
See More
Previous Close:
$50.60
Open:
$50.53
24h Volume:
783.12K
Relative Volume:
0.69
Market Cap:
$1.53B
Revenue:
$915.25M
Net Income/Loss:
$131.14M
P/E Ratio:
11.91
EPS:
4.472
Net Cash Flow:
$96.71M
1W Performance:
+3.72%
1M Performance:
+25.02%
6M Performance:
-43.60%
1Y Performance:
-58.00%
Inspire Medical Systems Inc Stock (INSP) Company Profile
Name
Inspire Medical Systems Inc
Sector
Industry
Phone
763-957-5037
Address
5500 WAYZATA BLVD, GOLDEN VALLEY
Compare INSP vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
INSP
Inspire Medical Systems Inc
|
53.27 | 1.46B | 915.25M | 131.14M | 96.71M | 4.472 |
|
ABT
Abbott Laboratories
|
101.66 | 175.37B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
319.14 | 122.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
83.29 | 106.50B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
43.77 | 65.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
85.00 | 49.36B | 6.30B | 1.07B | 1.09B | 1.8406 |
Inspire Medical Systems Inc Stock (INSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-12-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-12-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-22-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-26 | Downgrade | Truist | Buy → Hold |
| Dec-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-26-25 | Upgrade | Truist | Hold → Buy |
| Nov-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-24-25 | Upgrade | Stifel | Hold → Buy |
| Nov-04-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-22-25 | Downgrade | UBS | Buy → Neutral |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Aug-05-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-05-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Aug-05-25 | Downgrade | Truist | Buy → Hold |
| Nov-20-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-19-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-19-24 | Initiated | Morgan Stanley | Overweight |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Jan-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Dec-13-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-15-20 | Downgrade | Goldman | Buy → Neutral |
| Nov-03-20 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-03-20 | Upgrade | Oppenheimer | Underperform → Perform |
| Sep-22-20 | Initiated | JP Morgan | Overweight |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-15-20 | Initiated | Goldman | Buy |
| Jun-18-20 | Reiterated | Piper Sandler | Overweight |
| May-18-20 | Initiated | Lake Street | Buy |
| Apr-28-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-09-20 | Initiated | Piper Sandler | Overweight |
| Jan-28-20 | Initiated | Oppenheimer | Underperform |
| Jan-27-20 | Initiated | Oppenheimer | Underperform |
| Nov-06-19 | Upgrade | Berenberg | Sell → Hold |
| Feb-05-19 | Initiated | Dougherty & Company | Buy |
| Nov-28-18 | Initiated | Berenberg | Sell |
| Oct-29-18 | Initiated | Leerink Partners | Outperform |
| May-29-18 | Initiated | Guggenheim | Buy |
| May-29-18 | Initiated | Stifel | Buy |
| May-29-18 | Initiated | Wells Fargo | Outperform |
View All
Inspire Medical Systems Inc Stock (INSP) Latest News
A Look at Inspire Medical Systems Inc (INSP) After 5.3% Gain -- GF Value $215.85 vs Price $53.27 - GuruFocus
3 Medical Device Stocks Giving Investors a Different Healthcare Play - MarketBeat
Form 4 Inspire Medical Systems Inc For: 20 July By Investing.com - Investing.com Canada
Understanding Momentum Shifts in (INSP) - Stock Traders Daily
Price to earnings forward of Inspire Medical Systems, Inc. – NYSE:INSP - TradingView
Form 4 Inspire Medical Systems Inc For: 17 July By Investing.com - Investing.com Australia
Here's why you should retain INSP stock in your portfolio for now - MSN
Inspire Medical Systems (NYSE: INSP) director receives 581-share stock fee award - Stock Titan
Inspire Medical (NYSE: INSP) grants 346 shares to director Tansey - Stock Titan
ETFs Investing in Inspire Medical Systems, Inc. Stocks - TradingView
Here's Why You Should Retain INSP Stock in Your Portfolio for Now - Yahoo Finance
Frontier tech research, news & data - MLQ.ai
Inspire Medical (INSP) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
INSP Maintained by Truist Securities -- Price Target Raised to $54 - GuruFocus
Truist Adjusts Price Target on Inspire Medical Systems to $54 From $50, Maintains Hold Rating - Moomoo
Inspire Medical Systems, Inc. (INSP) Stock Analysis: Navigating Potential Amidst Robust Revenue Growth in the Medical Device Sector - DirectorsTalk Interviews
INSP Should I Buy - Intellectia AI
Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc.INSP - PR Newswire
Enterprise value to EBIT forward of Inspire Medical Systems, Inc. – NYSE:INSP - TradingView
Inspire Medical Systems (INSP) Faces A Fresh Test As Recalls Put Valuation In Focus - Yahoo Finance
Price to sales forward of Inspire Medical Systems, Inc. – NYSE:INSP - TradingView
Inspire Medical Systems (INSP) Short Interest & Short Float | Updated Jul 2026 $INSP - MarketBeat
2 Reasons INSP is Risky and 1 Stock to Buy Instead - Yahoo Finance
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Investors in Inspire Medical Systems, Inc. (INSP): Protect Your RightsContact Levi & Korsinsky Before January 5, 2026 - The National Law Review
Inspire Medical Systems (INSP) Could Be 5% Undervalued After Class II Device Recalls - Sahm
Inspire Medical Systems to report Q2 2026 results on August 3 - scanx.trade
Inspire Medical corrects Q2 2026 results date to Aug. 3 - Stock Titan
Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026 - The Manila Times
Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026 - The Manila Times
Inspire Medical sets Aug. 3 earnings call after Q2 results - Stock Titan
Inspire Medical Shareholder Alert - TMX Newsfile
Inspire Medical Systems (INSP) Stock Analysis: Navigating the Medical Device Market with a 10% Upside - DirectorsTalk Interviews
Inspire Medical Ongoing Deadline Alert - TMX Newsfile
Inspire Medical Systems (INSP) Gets a Hold from Wells Fargo - The Globe and Mail
Wells Fargo Maintains Inspire Medical Systems(INSP.US) With Hold Rating, Maintains Target Price $56 - Moomoo
Levi & Korsinsky Notifies Inspire Medical Systems, Inc. (INSP) InvestorsLead Plaintiff Deadline on January 5, 2026 - The National Law Review
Inspire Medical Systems (NASDAQ: INSP) D.E. Shaw affiliate reports 5.1% holding - Stock Titan
INSP - Finviz
Inspire Medical Systems CFO departs - MSN
Freedom Capital Markets Initiates Inspire Medical Systems(INSP.US) With Buy Rating, Announces Target Price $62 - Moomoo
INSP Initiates Coverage On Inspire Medical Systems -- Rating Buy - GuruFocus
Inspire Medical shares initiated at buy by Freedom Capital on valuation By Investing.com - Investing.com India
Inspire Medical shares initiated at buy by Freedom Capital on valuation - Investing.com South Africa
Investor Alert: Deadline Approaching to Join Inspire Medical Syst - The National Law Review
Inspire Medical Systems, Inc.(NYSE: INSP) added to Russell 2000 Index - marketscreener.com
Inspire Medical Systems, Inc.(NYSE: INSP) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Inspire Medical Systems, Inc.(NYSE: INSP) added to Russell 2000 Value Benchmark - marketscreener.com
Inspire Medical Systems, Inc.(NYSE: INSP) added to Russell 2000 Growth Benchmark - marketscreener.com
Inspire Medical Systems, Inc.(NYSE: INSP) dropped from Russell 1000 Dynamic Index - marketscreener.com
Inspire Medical Systems, Inc. (INSP) Stock Analysis: Navigating a 11.37% Potential Upside Amidst Mixed Analyst Ratings - DirectorsTalk Interviews
Inspire Medical Systems Inc Stock (INSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):